Lichtenstein A - Search Results

1

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses.

Hsu JH, Shi Y, Hu L, Fisher M, Franke TF, Lichtenstein A. Hsu JH, et al. Among authors: lichtenstein a. Oncogene. 2002 Feb 21;21(9):1391-400. doi: 10.1038/sj.onc.1205194. Oncogene. 2002. PMID: 11857082

2

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Shi Y, et al. Among authors: lichtenstein a. J Biol Chem. 2002 May 3;277(18):15712-20. doi: 10.1074/jbc.M200043200. Epub 2002 Feb 28. J Biol Chem. 2002. PMID: 11872747 Free article.

3

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A. Shi Y, et al. Among authors: lichtenstein a. Cancer Res. 2002 Sep 1;62(17):5027-34. Cancer Res. 2002. PMID: 12208757

4

Downstream effectors of oncogenic ras in multiple myeloma cells.

Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Hu L, et al. Among authors: lichtenstein a. Blood. 2003 Apr 15;101(8):3126-35. doi: 10.1182/blood-2002-08-2640. Epub 2002 Dec 19. Blood. 2003. PMID: 12515720 Free article.

5

Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.

Shi Y, Gera J, Hsu JH, Van Ness B, Lichtenstein A. Shi Y, et al. Among authors: lichtenstein a. Mol Cancer Ther. 2003 Jun;2(6):563-72. Mol Cancer Ther. 2003. PMID: 12813136

6

Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways.

Hsu JH, Shi Y, Frost P, Yan H, Hoang B, Sharma S, Gera J, Lichtenstein A. Hsu JH, et al. Among authors: lichtenstein a. Oncogene. 2004 Apr 22;23(19):3368-75. doi: 10.1038/sj.onc.1207459. Oncogene. 2004. PMID: 15021914

7

The AKT kinase is activated in multiple myeloma tumor cells.

Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A. Hsu J, et al. Among authors: lichtenstein a. Blood. 2001 Nov 1;98(9):2853-5. doi: 10.1182/blood.v98.9.2853. Blood. 2001. PMID: 11675360 Free article.

8

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.

Frost P, Shi Y, Hoang B, Lichtenstein A. Frost P, et al. Among authors: lichtenstein a. Oncogene. 2007 Apr 5;26(16):2255-62. doi: 10.1038/sj.onc.1210019. Epub 2006 Oct 2. Oncogene. 2007. PMID: 17016437

9

MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.

Shi Y, Frost P, Hoang B, Yang Y, Fukunaga R, Gera J, Lichtenstein A. Shi Y, et al. Among authors: lichtenstein a. Oncogene. 2013 Jan 10;32(2):190-7. doi: 10.1038/onc.2012.43. Epub 2012 Feb 27. Oncogene. 2013. PMID: 22370634 Free PMC article.

10

Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.

Shi Y, Yang Y, Hoang B, Bardeleben C, Holmes B, Gera J, Lichtenstein A. Shi Y, et al. Among authors: lichtenstein a. Oncogene. 2016 Feb 25;35(8):1015-24. doi: 10.1038/onc.2015.156. Epub 2015 May 11. Oncogene. 2016. Retraction in: Oncogene. 2023 Sep;42(40):3016. doi: 10.1038/s41388-023-02820-5 PMID: 25961916 Free PMC article. Retracted.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

847 results

Search Page

Filters